2017 – Scrip Readers’ Pharma Year In Review
As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.
You may also be interested in...
Scrip takes a trip back through the highs of drug development, looking at successes including positive cardiovascular outcomes studies for cholesterol drugs, advances in cancer and breakthroughs in hemophilia.
The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.
You could be forgiven for thinking that Brexit was the only story in town on the European regulatory front in 2017, but there were of course plenty of other important developments during the year.